AD_____

Award Number: DAMD17-97-1-7031

TITLE: Assessment of the Activation State of Ras and Map Kinase
in Human Breast Cancer Specimens

PRINCIPAL INVESTIGATOR: Gerry R. Boss, M.D.

CONTRACTING ORGANIZATION: University of California, San Diego
La Jolla, California 92093-0934

REPORT DATE: January 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010427 084

REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE January 2001	3. REPORT TYPE AND DATES COVERED Final (1 Sep 97 - 31 Dec 00)

4. TITLE AND SUBTITLE
Assessment of the Activation State of Ras and Map Kinase in Human Breast Cancer Specimens

5. FUNDING NUMBERS
DAMD17-97-1-7031

6. AUTHOR(S)
Gerry R. Boss, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of California. San Diego
La Jolla, California 920093-0934

E-Mail: gboss@ucsd.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

Although genetic *ras* mutations are infrequent in breast cancer, Ras may be pathologically activated in breast cancer by overexpression of growth factor receptors which signal through Ras. We measured Ras activation in 20 human breast cancers and seven non-malignant breast samples and found Ras was highly activated in 11 of the cancers, i.e., more than two standard deviations above the mean of the benign samples; seven of these 11 cancers expressed both the epidermal growth factor (EGF) and the ErbB-2/*neu*/HER-2 receptors with the remaining four cancers with high Ras activation expressing one of these two receptors. In the remaining 9 cancers, Ras activation was similar to that observed in the benign breast samples with none of these cancers expressing the EGF receptor while one expressed the ErbB-2 receptor. None of the cancers tested had an activating K-*ras* mutation. The activity of mitogen-activated protein (MAP) kinase was high in the cancers and reflected the degree of Ras activation. In cultured mammary tumor cell lines, we showed that Ras activation was ligand dependent in cells overexpressing the ErbB-2 receptor. Thus, Ras is abnormally activated in breast cancers overexpressing the EGF and/or ErbB-2 receptors indicating there are sufficient ligands *in vivo* to activate these receptors and this work provides a basis for new target-based treatments of human breast cancer.

14. SUBJECT TERMS
Breast Cancer

15. NUMBER OF PAGES
21

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

TABLE OF CONTENTS

INTRODUCTION

Ras is an important cellular switch and alternates between an active GTP-bound state and an inactive GDP-bound state. It transmits growth-promoting signals from the plasma membrane to the nucleus via one of several pathways including the Raf/MEK/ERK transduction pathway (1). Activating mutations of the *ras* gene are common in some cancers and occur in about 90% of pancreatic cancers, 50% of colon cancers, and 50% of thyroid cancers. However, activating *ras* mutations are infrequent in other cancers, including breast cancers where only about 5% of tumors exhibit a *ras* mutation (1; 2). The low percentage of breast cancers with activating *ras* mutations has suggested that Ras does not play an important pathogenetic role in this cancer (3). Yet several growth factor receptors which relay signals through Ras are overexpressed in breast cancer suggesting that Ras may be activated in some breast cancers through an "upstream" mechanism (4-10). Two of these growth factor receptors are the epidermal growth factor (EGF) receptor and the ErbB-2/*neu*/HER-2 receptor. These two receptors are overexpressed in 20-50% of human breast cancers and their increased expression predicts shortened disease-free survival and overall survival (4; 5; 11; 12). In addition, a mutated constitutively-active EGF receptor has been reported in breast cancer and the c-FMS/colony stimulating factor-1 (CSF-1) receptor, which can also signal through Ras, is expressed in ~15% of breast cancers but not in normal breast tissue (13-15). Although high expression of the EGF and ErbB-2 receptors correlates with a poor prognosis in breast cancer, it is not known whether sufficient ligands are present in breast tissue to activate the receptors and which of the signal transduction pathways activated by the receptors in cultured cells are activated in primary cancers (4; 5; 11; 12).

BODY

During the tenure of the grant, we analyzed 20 breast cancer samples for Ras activation as well as EGF and ErbB-2 receptor expression; the breast cancers were compared to seven normal breast samples and two fibroadenomas. These data were presented in abstract form at the Era of Hope Meeting in Atlanta, June, 2000 and were recently published: *Breast Cancer Research and Treatment* 62: 51-62, 2000. We define abnormal Ras activation as activation levels that are greater than two standard deviations above the mean of the normal samples we have analyzed. In the breast cancers we found a striking correlation between increased Ras activation and overexpression of the EGF and/or ErbB-2 receptors: 11 of the breast cancers showed increased Ras activation and seven of these overexpressed both the EGF and ErbB-2 receptors while the other four with increased Ras activation overexpressed one of these two receptors (Group B cancers in Fig. 2 of the published paper). These data are markedly different than data from the nine cancers with normal Ras activation levels in which none overexpressed the EGF receptor and only one overexpressed the ErbB-2 receptor (Group A cancers in Fig. 2 of the paper). Thus, there was a remarkable correlation between increased expression of the EGF and/or ErbB-2 receptors and increased Ras activation. The vast majority of *ras* mutations that occur in breast cancer are in K-*ras*, codon 12; we did not find a mutation at this site in any of the cancers, consistent with the low rate of activating *ras* mutations in breast cancer, and thus the increased Ras activation we observed was not from a genetic *ras* mutation. None of the cancers we analyzed expressed the truncated constitutively active EGF

4

receptor or the c-FMS/CSF-1 receptor. We found increased activation of mitogen-activated protein (MAP) kinase in the cancers with increased Ras activation, indicating that Ras signals through the Raf kinase, MEK, MAP kinase pathway in breast cancer.

In addition to studying primary breast cancers, we also studied three different breast cancer cell lines, one without any known genetic mutations, one with an activating K-*ras* mutation and one which overexpressed the ErbB-2 receptor. We found that the degree of Ras activation in the cancers with high Ras activation was similar to the cell line with the K-*ras* mutation and the cell line overexpressing the ErbB-2 receptor. Ras activation in the cancers with low Ras activation was similar to that found in the cell line without a known genetic mutation. Thus, there was a good correlation between the data from the primary cancers and the data from the cell lines. In addition, in the cell line overexpressing the ErbB-2 receptor, growth factors were required to activate Ras; since we found Ras to be highly activated in cancers overexpressing the EGF and/or ErbB-2 receptors, this indicates there are sufficient ligands in breast tissue *in vivo* to activate Ras.

This study provides a strong basis for treating selected breast cancers with inhibitors of the Ras/MAP kinase pathway. In addition to pharmacologic agents, there are antibodies and oncolytic viruses which target the Ras/MAP kinase pathway suggesting that these various approaches could be of value in the treatment of breast cancer (16; 17). As part of another research project, we have developed an instrument to automate our method for measuring Ras activation in primary cancers and we are now ready to test the prototype instrument. Ultimately, this instrument should allow measuring Ras activation in clinical laboratories and the work funded by the present grant proposal will, therefore, represent the initial studies of Ras activation in breast cancer.

Although it was not part of the original grant application, we have also begun to assess the activation state of Rho in breast cancers. Rho proteins are related to Ras and like Ras cycle between an active GTP-bound state and an inactive GDP-bound state. They are necessary for *ras*-transformation and regulate cell morphology, adhesion, and motility through cytoskeletal dynamics and play an important role in carcinogenesis (18). Rho proteins are involved in the changes in cell attachment and migration that are required for tumor cell invasion and metastasis (19; 20). Thus, we decided to assess Rho activation in primary and metastatic breast cancers. In order to perform these measurements, we first had to develop an assay for measuring Rho activation. Unlike for Ras, a good immunoprecipitating antibody against Rho is not available. Thus, we have used the Rho binding domain of the Rho effector Rhotekin (21; 22). This protein binds with a very high affinity to activated Rho, i.e., Rho in the GTP-bound state but not to Rho in the unactivated GDP-bound state. In primary breast samples, measuring active Rho would not be sufficient since tissue heterogeneity could lead to markedly different amounts of Rho in different samples. We, therefore, devised a method to measure GDP-bound Rho which takes advantage of the fact that the exchange of GTP for GDP on Rho takes place very quickly in the absence of magnesium. Thus, we split the samples in half and incubate one half with exogenous GTP; since we extract the cells in Triton X-114, excess GTP can be removed by three rapid and successive phase extractions. We have found this method to be highly accurate in pilot studies performed on the breast cancer cell lines described above. To date, we have assessed Rho activation in benign breast tissue from four subjects and in five breast cancers. Interestingly, Rho was much more activated in four of the five cancers compared to the two normal breast samples. Clearly, much more work needs to be done using this newly-developed technology. Recent work has shown that farnesyl transferase

inhibitors, which were originally developed as Ras inhibitors, may actually function by inhibiting Rho (23; 24). Thus, assessing a tumor for its degree of Rho activation may provide data concerning whether a farnesyl transferase inhibitor would be of use in treating the cancer. Determining which breast cancers might be treated with a farnesyl transferase inhibitor was one of the objectives of the original grant application.

KEY RESEARCH ACCOMPLISHMENTS
- Ras is activated in primary human breast cancers in the absence of a mutation in the *ras* gene
- Ras activation occurs in tumors with overexpression of the EGF and/or ErbB-2 receptors
- Ras activation in breast cancer correlates with MAP kinase activity
- In a human breast cancer cell line overexpressing the ErbB-2 receptor, Ras activation occurred only when the cells were exposed to sufficient ligand
- In breast cancers overexpressing the EGF or ErbB-2 receptors, there are sufficient ligand *in vivo* to activate the receptors and, thereby, activate Ras.
- Rho may be activated in a significant number of breast cancers

REPORTABLE OUTCOMES
A paper has been published (*Breast Cancer Research and Treatment* 62: 51-62, 2000) describing the results from this study; it is provided in the Appendix. In addition, an abstract was presented at the Era of Hope Meeting, Atlanta, Georgia, June, 2000.

CONCLUSIONS
This work shows definitively that Ras is activated in approximately half of all human breast cancers. This is an important finding because it indicates that patients who have tumors with high Ras activation are candidates for therapies aimed at Ras or other protein targets in the Ras/MAP kinase pathway. Once the method for measuring Ras activation becomes automated, assessing Ras activation in tumors may become important clinical information.

REFERENCES
1. Barbacid, M. *Ras* genes. Annu.Rev.Biochem., *56*: 779-827, 1987.

2. Bos, J.L. *ras* oncogenes in human cancer: A review. Cancer Research, *49*: 4682-4689, 1989.

3. Dickson, R.B., Gottardis, M.M., and Merlino, G.T. Molecular insights into breast cancer from transgenic mouse models. BioEssays, *13*: 591-596, 1991.

4. Slamon, D., Clark, G., Wong, S., Levin, W., Ullrich, A., and McGuire, W. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/*neu* oncogene. Science, *235*: 177-182, 1987.

5. Lacroix, H., Iglehart, J.D., Skinner, M.A., and Kraus, M.H. Overexpression of *erbB*-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene, *4*: 145-151, 1989.

6. Clark, G.J. and Der, C.J. Aberrant function of the Ras signal transduction pathway in human breast cancer. Br.Can.Res.Treat., *35*: 133-144, 1995.

7. Klijn, J., Berns, P., Schmitiz, P., and Foekens, J. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocrine Rev., *13*: 3-17, 1992.

8. Sainbury, J.R., Farndon, J.R., Needham, G.K., Malcolm, A.J., and Harris, A.J. Epidermal-growth-factor receptor status as predictor of early recurrence of death from breast cancer. Lancet, 1398-1402, 1987.

9. Newby, J.C., Hern, R.P., Leek, R.D., Smith, I.E., Harris, A.L., and Dowsett, M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clincal relevance in breast cancer. Br.J.Cancer, *71*: 1237-1242, 1995.

10. Earp, S.H., Dawson, T.L., Li, X.0., and Yu, H. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Br.Can.Res.Treat., *35*: 115-132, 1995.

11. Slamon, D.J., Godolphin, W., Jones, L., Holt, J., Wong, S., Keith, D., Levin, W., Stuart, S., Udove, J., Ullrich, A., and Press, M. Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer. Science, *244*: 707-712, 1989.

12. Iglehart, J.D., Kraus, M.H., Langton, B.C., Huper, G., Kerns, B.J., and Marks, J.R. Increased *erb*B-2 gene copies and expression in multiple stages of breast cancer. Cancer Res., *50*: 6701-6707, 1990.

13. Moscatello, D.K., Holgado-Madruga, M., Godwin, A.K., Ramirez, G., Gunn, G., Zoltick, P.W., Biegel, J.A., Hayes, R.L., and Wong, A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res., *55*: 5536-5539, 1995.

14. Kacinski, B.M. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann.Med., *27*: 79-85, 1995.

15. Kacinski, B.M., Scata, K.A., Carter, D., Yee, L.D., Sapi, E., King, B.L., Chambers, S.K., Jones, M.A., Pirro, M.H., Stanley, E.R., and Rohrschneider, L.R. *FMS* (CSF-1 receptor) and CSF-1

transcripts and protein are expressed by human breast carcinomas *in vivo* and *in vitro*. Oncogene, *6*: 941-952, 1991.

16. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J., Rosen, P.P., Twaddell, T., Henderson, I.C.a., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J.Clin.Oncol., *14*: 737-744, 1996.

17. Coffey, M.C., Strong, J.E., Forsyth, P.A., and Lee, P.W.K. Reovirus therapy of tumors with activated Ras pathway. Science, *282*: 1332-1334, 1998.

18. Hall, A. Rho GTPases and the actin cytoskeleton. Science, *279*: 509-514, 1998.

19. Aspenström, P. The Rho GTPases have multiple effects on the actin cytoskeleton. Exp.Cell Res., *246*: 20-25, 1999.

20. del Peso, L., Hernández-Alcoceba, R., Embade, N., Carnero, A., Esteve, P., Paje, C., and Lacal, J.C. Rho proteins induce metastatic properties *in vitro*. Oncogene, *15*: 3047-3057, 1997.

21. Reid, T., Furuyashiki, T., Ishizaki, T., Watanabe, G., Watanabe, N., Fujikawa, K., Morii, N., Madaule, P., and Narumiya, S. Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the Rho-binding domain. J Biol Chem, *271*: 13556-13560, 1996.

22. Ren, X.-D., Kiosses, W.B., and Schwartz, M.A. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J., *18*: 578-585, 1999.

23. Lebowitz, P.F., Casey, P.J., Prendergast, G.C., and Thissen, J.A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J.Biol.Chem., *272*: 15591-15594, 1997.

24. Du, W., Lebowitz, P.F., and Prendergast, G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol.& Cell.Biol., *19*: 1831-1840, 1999.

BIBLIOGRAPHY

Publication

1.	Von Lintig, F.C., Dreilinger, A.D., Varki, N.M., Wallace, A.M., Casteel, D.E., and Boss, G.R. Ras Activation in Human Breast Cancer. *Breast Cancer Research and Treatment* 62: 51-62, 2000

Abstract

1.	Von Lintig, F.C., Dreilinger, A.D., Varki, N.M., Wallace, A.M., Casteel, D.E., and Boss, G.R. Ras Activation in Human Breast Cancer. Era of Hope Meeting, Atlanta, Georgia, June, 2000.

PERSONNEL LIST

Gerry R. Boss, M.D., Principal Investigator

Anna D. Dreilinger, M.D., Co-Investigator

Anne M. Wallace, M.D., Co-Investigator

Ras activation in human breast cancer

Friederike C. von Lintig[1], Anna D. Dreilinger[2], Nissi M. Varki[1], Anne M. Wallace[3], Darren E. Casteel[1], and Gerry R. Boss[1]
[1]*Departments of Medicine,* [2]*Pathology and* [3]*Surgery and* [1,2,3]*Cancer Center, University of California, San Diego, La Jolla, CA, USA*

Key words: breast cancer, epidermal growth factor receptor, ErbB-2 receptor, mitogen-activated protein kinase, ras

Summary

Genetic *ras* mutations are infrequent in breast cancer but Ras may be pathologically activated in breast cancer by overexpression of growth factor receptors which signal through Ras. Using a highly sensitive, coupled enzymatic assay, we measured Ras activation in 20 breast cancers, two fibroadenomas, and seven normal breast samples. Ras was highly activated compared to benign tissue in 11 of the 20 cancers; 7 of these 11 cancers expressed both the epidermal growth factor (EGF) and ErbB-2/*neu*/HER-2 receptors with the remaining four cancers with high Ras activation expressing one of these two receptors. In the other nine cancers, Ras activation was similar to that observed in benign breast tissue with none of these cancers expressing the EGF receptor while one expressed the ErbB-2 receptor. None of the cancers tested had an activating K-*ras* mutation nor did any of the cancers express a truncated EGF receptor or the c-FMS receptor. The activity of mitogen-activated protein (MAP) kinase was high in the cancers, and reflected the degree of Ras activation. In cultured mammary tumor cell lines, we showed that Ras activation was ligand dependent in cells overexpressing the ErbB-2 receptor. Thus, Ras was abnormally activated in breast cancers overexpressing the EGF and/or ErbB-2 receptors indicating there are sufficient ligands *in vivo* to activate these receptors, and this work provides a basis for new target-based treatments of this disease.

Introduction

Ras, the product of the *ras* proto-oncogene, alternates between an active GTP-bound state and an inactive GDP-bound state and transmits growth-promoting signals from the plasma membrane to the nucleus [1]. Activating mutations of codons 12, 59 or 61 of Ras can lead to malignant transformation and are found in a variety of human cancers, including about 90% of pancreatic cancers, 50% of colon cancers, 50% of thyroid cancers and 5% of breast cancers [1, 2].

The low percentage of breast cancers with activating *ras* mutations has led to the notion that Ras does not play an important pathogenetic role in this cancer [3]. However, several growth factor receptors which signal through Ras are overexpressed in breast cancer suggesting that Ras may be activated in some breast cancers through upstream mechanisms [4–10]. Two of these growth factor receptors are the EGF[1]

and the ErbB-2/*neu*/HER-2 receptor. They are over-expressed in 20–50% of human breast cancers and their increased expression is associated with shortened disease-free survival and overall survival [4, 5, 11, 12]. In addition, a truncated constitutively-active EGF receptor, ΔEGFR which lacks 267 amino acids in the receptor's extracellular domain, has been reported in breast cancer and the c-FMS/colony stimulating factor-1 receptor, which also signals through Ras, is expressed in ~15% of breast cancers but not in normal breast tissue [13–15]. While high expression of the EGF and ErbB-2 receptors are poor prognostic factors in breast cancer, it is not known whether sufficient ligands are present in breast tissue to activate the receptors and which of the signal transduction pathways activated by the receptors in cultured cells is/are activated in primary cancers [4, 5, 11, 12]. Increased activity of MAP kinase has been reported in breast cancer [16], but this enzyme can be activated by

more than one mechanism and Ras activates more than MAP kinase in transmitting pro-proliferative signals [17, 18].

We investigated the activation state of Ras in 20 human breast cancers and compared the data to those obtained in seven normal breast samples, two fibroadenomas and three cultured human breast cancer cell lines, one without any known genetic mutations, one which overexpresses the ErbB-2 receptor and one which has an activating K-*ras* mutation. When compared to benign breast tissue, 11 of the 20 breast cancers demonstrated a two to six-fold increase in Ras activation and greater than a five-fold increase in MAP kinase activity. All 11 of these cancers showed increased expression of the EGF and/or ErbB-2 receptors. The degree of Ras activation in the 11 cancers was similar to that observed in the ErbB-2-overexpressing cell line treated with growth factors and in the cell line with a K-*ras* mutation under all culture conditions. As Ras is the target of new pharmacologic and viral oncotherapeutic agents [19–23], this work provides a rationale for novel treatment strategies of breast cancer.

Methods

Harvesting of human breast tissue for measurement of ras activation

Human breast tissue was obtained according to a procedure approved by the UCSD IRB. The pathologist sectioned routine surgical specimens and applied tissue scrapings to glass slides on dry ice; approximately 1×10^6 cells were obtained per slide, and cells were frozen between 5 and 15 min of surgical resection. Only samples which yielded > 80% epithelial cells were analyzed further. Figure 1 shows representative scrapings from normal and malignant tissue stained histochemically and with an anti-keratin antibody. By taking serial sections every 5 min from a large tumor, we showed that Ras activation is stable if cells are frozen within 20 min of surgical resection. In addition, by comparing freshly harvested samples to frozen samples, we showed that slides can be stored at −80°C for several months without any change in Ras activation. There was no preselection of patient samples. However, there was an inherent bias towards tumors of > 1 cm in size because they were more likely to be found quickly and provide sufficient material.


Figure 1. Characterization of cells analyzed for ras activation. Benign breast tissue from patient number 1 (panel A) or malignant tissue from patient 11 (panel B) and patient 21 (panel C) was sectioned in the operating room and cells adherent to the scalpel blade were applied to glass slides on dry ice which were either stained with Wright's stain (panels A and B) or with an immunohistochemical stain using an anti-keratin antibody. The scale bar in all three panels is 50 μm. Note that the majority of cells are epithelial in origin, both in the benign and malignant samples.

Measurement of Ras activation

Ras activation is defined as the percent of Ras molecules in the active GTP-bound state, i.e., (Ras-bound GTP/Ras-bound GDP + Ras-bound GTP) × 100, and was measured as previously described using enzyme-based methods [24–27]. Briefly, frozen cells from two to three glass slides were lysed and either the rat monoclonal antibody Y13-259 (experimental sample)

or nonspecific rat IgG (control sample) was added to the lysate; antibody Y13-259 is a pan-Ras antibody which recognizes all three forms of Ras, i.e., H-, K- and N-Ras. GTP and GDP were eluted from the immunoprecipitated Ras by heating to 100°C for 3 min. We have found that a 1 h incubation of the primary antibody (Y13-259) with cell extracts is sufficient to quantitatively immunoprecipitate Ras [24]; magnesium ion and high salt present in the buffer inhibit GTP/GDP dissociation from Ras and RasGAP activity, respectively, and antibody Y13-259 is a Ras neutralizing antibody which inhibits RasGEF and RasGAP from interacting with Ras [28]. We have shown that antibody Y13-259 is superior to antibody Y13-238 for immunoprecipitating Ras, even though the latter antibody could, theoretically, precipitate Ras bound to its downstream effectors [29]. We have shown in experiments where Ras was immunoprecipitated from cells previously incubated with $^{32}PO_4$ that the heating step quantitatively elutes GDP and GTP from Ras. In addition, we have shown by high performance liquid chromatography that at neutral pH less then 5% of GTP is destroyed when heated to 100°C for up to 10 min [24].

GTP was measured by converting it to ATP using the enzyme nucleoside diphosphate kinase (Sigma, St. Louis, MO) and ATP was measured by the luciferase/luciferin system according to the following reactions:

nucleoside diphosphate kinase

$$GTP + ADP \longrightarrow GDP + ATP$$

luciferase

$$ATP + luciferin \longrightarrow oxyluciferin + AMP$$

$$+ pyrophosphate + light$$

GDP was measured by converting it to GTP using pyruvate kinase and phosphoenolpyruvate with the GTP measured as described above:

pyruvate kinase

$$GDP + phosphoenolpyruvate \longrightarrow GTP + pyruvate.$$

Both assays are sensitive to 1 fmol of nucleotide. When GTP is measured in the second step of the GDP assay, the sum of GTP + GDP is determined. Thus, the amount of GTP in the sample must be subtracted from the amount of GTP + GDP to yield the amount of GDP.

The amounts of GDP and GTP in the samples were determined by subtracting the control sample from the experimental sample and then comparing the results with standard curves prepared with each sample set. The data are expressed as fmol of GTP or GDP per microgram of DNA.

Assessment for activating mutations in k-ras, codon 12

DNA was isolated from frozen tissue or from paraffin blocks using a commercial kit (Puregene, Minneapolis, MN) and activating mutations in K-*ras*, codon 12 were detected by polymerase chain reaction (PCR)/restriction fragment length polymorphism using ~400 ng DNA template [30]. PCR amplification of K-*ras* exon I sequences generates a DNA fragment of 157 bp; digestion of wild type sequences with the restriction enzyme BstNI yields fragments of 114, 29 and 14 bp whereas sequences containing a codon 12 mutation, first or second position, are cleaved only once resulting in fragments of 143 and 14 bp [30]. A human pancreatic cancer with a K-*ras*, codon 12 mutation and the human breast cancer cell line MCF-7 containing wild type K-*ras* served as controls.

Immunohistochemistry

Paraffin-embedded tissue was incubated with a rabbit anti-EGF receptor polyclonal antibody (Santa Cruz Biotechnology), a rabbit anti-ErbB-2 receptor polyclonal antibody (Dako), a mouse anti-ΔEGFR monoclonal antibody (provided by A. Jungbluth of the Ludwig Institute, New York, NY), a rabbit anti-cFMS receptor polyclonal antibody (Santa Cruz Biotechnology), or a rabbit anti-keratin polyclonal antibody (Dako). The anti-ΔEGFR antibody does not cross-react with the full-length wild type EGF receptor [27]. Antibodies were detected using an alkaline phosphatase kit (Dako) and slides were counterstained with nuclear fast red. Staining of > 20% of the cells on the plasma membrane was considered positive. Immunohistochemical analysis of EGF and ErbB-2 receptor expression correlates well with results from northern, Southern and western blotting and ligand-binding assays [9, 11].

Measurement of MAP kinase activity

MAP kinase activity was measured by following phosphorylation of myelin basic protein in MAP kinase immunoprecipitates as previously described [29]. Data

are expressed as pmol/min/mg protein, and the assay was linear with time and protein concentration.

Breast cancer cell lines

The human breast cancer cell lines MCF-7, MDA-MB-453 and MDA-MB-231 were obtained from the American type culture collection. Cells were grown in D-MEM/F-12 medium containing 8% transferrin-enriched calf serum and 2% fetal bovine serum (FBS). For measurement of Ras and MAP kinase activation under logarithmic growth, cells were harvested in mid-logarithmic phase and for growth factor stimulation experiments, cells were starved for 72 h in D-MEM/F-12 without serum, and then incubated for 5 min with D-MEM/F-12 containing either 20% FBS or 100 ng/ml EGF. In some experiments, the anti-ErbB-2 monoclonal antibody 9G6 directed against an external epitope (Santa Cruz Biotechnology) was added at the time of transfer to serum-free medium. At the time of harvest, cells were washed once with ice-cold phosphate-buffered saline, scraped from the plates and collected by centrifligation. Cell pellets were frozen immediately on dry ice and kept at −80°C until extracted for Ras activation or MAP kinase activity.

Measurement of DNA and protein

DNA was measured by fluorescence using bisbenzimidazole [31] and protein was measured by the Bradford method [32].

Statistical evaluation of data

Comparison of data groups was done by the two-tailed Student t-test, with a p value of < 0.05 considered significant.

Results

Clinical and pathological data

The clinical and pathological data of the patient cohort are shown in Tables 1–3; Ras activation is included to allow direct comparison between the tables and Figure 2.

We obtained normal breast epithelial cells from seven subjects: in four cases from a reduction mammoplasty with three of the patients previously having had a cancer in the contralateral breast and in three


Figure 2. Ras activation and EGF and ErbB-2 expression in patient cohort. Cells from resected tissue were frozen rapidly on glass slides as described in Figure 1; Ras was immunoprecipitated from the cells and Ras activation was measured as described in Methods. Each circle represents Ras activation of one patient in the study cohort and is the mean of at least two independent measurements performed in duplicate. The wide horizontal bars show the mean value for each data set and, for the normal breast samples, the two narrow bars show two standard deviations beyond the mean. Of the 20 cancers, nine had Ras activation levels within two standard deviations of the mean value of the normal breast samples (group A cancers) and 11 cancers had Ras activation levels greater than two standard deviations above the mean of the normal samples (group B cancers); the mean Ras activation of the group B cancers was significantly different from the normal samples ($p < 0.05$). EGF and ErbB-2 receptor expression were assessed by immunohistochemical staining of paraffin-embedded tissue as described in Methods: open circles, negative staining for both receptors; filled circles, positive staining for both receptors; circles with left-half filled, positive staining for EGF receptor; circles with right-half filled, positive staining for ErbB-2 receptor.

cases at the time of mastectomy for a cancer (Table 1), in patient 3, the cancer was also analyzed (Table 3). In addition, two fibroadenomas were analyzed (Table 1).

We studied breast cancers from 20 patients and divided these patients into two groups based on Ras activation (described below). The age range and clinical stage and tumor size, grade and histology were

Table 1. Clinical and pathological data: normal breast tissue and fibroadenoma

Pt	Age	Histology	Ras activation (%)	Other
1	50	nl breast	1.0	DCIS in other breast
2	42	nl breast	2.1	ca in other breast, NOS
3	60	nl breast	4.9	invasive ductal ca in both breasts
4	68	nl breast	5.5	invasive lobular ca in same breast
5	70	nl breast	5.6	invasive lobular ca in same breast
6	52	nl breast	5.7	DCIS in same breast
7	33	nl breast	6.8	breast reduction
8	19	fibroadenoma	3.6	
9	70	fibroadenoma	6.4	

Tables 1–3. All patients were operated on at UCSD Medical Center as part of their routine clinical care. Estrogen and progesterone receptor status, the percentage of cells in S phase and chromosomal ploidy were determined as part of the clinical management of the patients according to standard procedures. For Ras activation measurements, tissue was obtained according to a procedure approved by the UCSD Institutional Review Board and was frozen within minutes of resection and analyzed as described in Materials and methods. Abbreviations are: nl breast: benign breast tissue with or without fibrocystic changes; ca: cancer; DCIS: ductal carcinoma *in situ*; LCIS: lobular carcinoma *in situ*; NOS: not otherwise specified; LN: lymph node; ER: estrogen receptor; PR: progesterone receptor; ND: not determined; NA: not applicable, this refers to the specific site from which the sample was taken for the Ras activation measurement, not for the cancer listed under 'other'.

similar in the two groups as were the percent cells in S phase, chromosomal ploidy and estrogen and progesterone receptor status (Tables 2 and 3).

Ras activation in human breast tissue

In the seven normal breast samples, Ras activation varied between 1.0 and 6.8% with a mean value of 4.5% (Table 1 and Figure 2). This degree of Ras activation is similar to what we have found in other normal human tissues including brain [26], peripheral nerve [25], and ovarian epithelium (unpublished data). Ras activation in the two fibroadenomas was similar to the normal breast tissue (Table 1 and Figure 2).

Ras activation in the 20 breast cancers varied between 1.5 and 29% (Tables 2 and 3 and Figure 2). In nine of the cancers, Ras activation was within two standard deviations of the mean of the normal

breast samples (0.3–8.7%) and these nine breast cancers were combined as group A in Table 2 and Figure 2, two of these cancers were from a lymph node metastasis with the primary lesion unavailable. In the remaining 11 cancers, Ras activation exceeded two standard deviations above the mean of the normal samples and these cancers were combined as group B in Table 3 and Figure 2. The mean Ras activation for the 11 group B cancers was 17%, or approximately four times the mean Ras activation of the normal breast samples; this degree of Ras activation was significantly higher than in the normal breast samples or in the Group A cancers ($p < 0.05$ for both comparisons). The increased Ras activation in the group B cancers was unlikely due to a generalized increase in Ras activation in the breast tissue of these patients because normal breast tissue from patient 3 exhibited similar Ras activation as in the other normal samples (Table 1).

Assessment for activating mutations in k-ras, codon 12

Increased Ras activation in the 11 group B cancers could be secondary to an activating mutation in one of the three *ras* genes. Activating *ras* mutations are infrequent in breast cancer (~5%) but, when present, the majority are in K-*ras*, codon 12 [2, 33, 34]. We found no K-*ras*, codon 12 mutations in seven group A cancers (patients 10, 11, 12, 14, 15, 16 and 17) or eight group B cancers (patients 3, 19, 20, 21, 22, 23, 26 and 28), including cancers with Ras activation > 20% (Figure 3 shows five representative samples). Results are not available for two group A and three group B cancers because of insufficient tissue. As expected, normal breast tissue and the fibroadenomas expressed wild type *ras*.

Expression of the EGF, ErbB-2 and c-FMS receptors

Since none of the breast cancers examined showed a K-*ras* mutation, increased Ras activation in these cancers could be secondary to overexpression of the EGF, ErbB-2 or c-FMS receptor. Receptor expression was assessed independently by two immunopathologists without knowledge of the samples' Ras activation. Figure 4 shows representative examples of ErbB-2 and EGF receptor staining and cumulative results for EGF and ErbB-2 receptor expression are shown in Figure 2. All normal breast tissues were negative for expression of the EGF receptor while two normal breast samples expressed the ErbB-2 receptor (patients

Table 2. Clinical and pathological data: breast cancers, group A

Pt	Age	Histology	Tumor size and lymph nodes	Stage	ER/PR	S-phase (%) ploidy	Ras activation (%)	Other
10	49	LCIS	NA	NA	NA	NA	1.5	Concurrent invasive lobular ca
11	53	Invasive ductal	2.2 cm 1/10 LN+	IIB (T2N1M0)	+/+	8.5 tetraploid	1.9	
12	44	Invasive ductal	3 cm 3/11 LN+	IIB (T2N1M0)	−/−	14.5 aneuploid	2.6	
13	65	Invasive lobular, inflammatory	4 cm	IIIB (T4N×M×)	+/+	9.2 aneuploid	3.1	History of ipsilateral medullary ca
14	56	Invasive ductal	1.5 cm 2/11 LN+	IIA (T1N1M0)	+/+	3.5 diploid	3.3	After neoadjuvant chemotherapy
15	62	Metastatic ductal in LN	NA	NA	NA	NA	4.3	Primary ca stage IIA, T1N1M0
16	66	Invasive lobular	8.0 cm	IIB (T3N0M0)	+/+	ND aneuploid	6.1	
17	56	Metastatic ductal in LN	NA	NA	NA	NA	6.5	Primary ca stage IV, T1N2M1
18	58	Invasive ductal	1.5 cm	I (T1N0M0)	−/−	14.8 aneuploid	8.5	

Table 3. Clinical and pathological data: Breast cancers, group B

| Pt	Age	Histology	Tumor size and lymph nodes	Stage	ER/PR	S-phase (%) ploidy	Ras activation (%)	Other
19	52	Invasive ductal	3.9 cm	IIA (T2N0M0)	+/+	9.3 aneuploid	9.8	
20	46	Invasive ductal	6.3 cm 1/11 LN+	IIIA (T3N1M0)	+/+	ND	9.9	After neoadjuvant chemotherapy
21	62	Invasive ductal	4.5 cm	IIB (T2N0M0)	−/−	8.8 aneuploid	12	
22	44	High grade DCIS	0.9 cm	stage 0 (Tis)	NA	NA	12	
23	48	LCIS	NA	NA	NA	NA	13	Ipsilateral invasive lobular ca, 3/13 LN+
24	34	Invasive ductal	3.3 cm	IIA (T2N0M0)	−/−	7.7 diploid	16	
25	41	Invasive lobular	7.0 cm 2/13LN+	III A (T3N1M0)	+/+	6.1 diploid	18	
3	60	Invasive ductal	1.0 cm	I (T1NXM0)	+/−	3.1	21	See patient 3, Table 1; third primary ca
26	37	Invasive ductal	5.5 cm 8/15 LN+	IV (T3N1M1)	+/+	ND	23	History of metastatic ca in contralateral breast
27	49	Invasive ductal	2.2 cm 2/2 LN+	IIB (T2N1M0)	+/+	9.3 aneuploid	24	
28	72	High grade DCIS	2.0 cm	stage 0 (Tis)	NA	NA	29	Paget's disease of ipsilateral nipple

Figure 3. Assessment for activating mutations in K-*ras*, codon 12. DNA was extracted from frozen or paraffin-embedded tissue and assessed for activating K-*ras*, codon 12 mutations as described in Methods. In each set of two lanes, the PCR product was incubated in the absence (a) or presence (b) of the restriction enzyme BstNI. Wild type K-*ras* yields a 114 bp cleavage fragment while K-ras, codon 12 mutations yield a 143 bp cleavage fragment; smaller fragments which were generated are not visualized. Lanes 1a & b, MCF-7 breast cancer cells which contain wild type Ras; lanes 2a & b, a human pancreatic cancer which is heterozygous for a K-*ras*, codon 12 mutation; lanes 3a & b, patient 10; lanes 4a & b, patient 15; lanes 5a & b, patient 23; lanes 6a & b, patient 26; and lanes 7a & b, patient 28.

2 and 4, Table 1). In a recent study, 40 of 291 benign breast samples expressed the ErbB-2 receptor [35]. Neither of the two fibroadenomas expressed the EGF or ErbB-2 receptor. None of the group A cancers expressed the EGF receptor while one expressed the ErbB-2 receptor. Nine of the 11 group B cancers expressed the EGF receptor and nine expressed the ErbB-2 receptor. None of the samples expressed the c-FMS receptor nor the constitutively-active ΔEGFR although we found positive membrane staining for these two receptors in human lymphoid tissue and in the U87MG glioblastoma cell line, respectively [27].

Thus, of the 11 Group B breast cancers with high Ras activation, seven co-expressed both the EGF and ErbB-2 receptor and the remaining four expressed either the EGF or ErbB-2 receptor. This is in contrast to the group A cancers with low Ras activation where one of nine expressed the ErbB-2 receptor.

MAP kinase activity in human breast tissue

To determine if high Ras activation led to high MAP kinase activity, we measured MAP kinase activity in samples with sufficient tissue (Figure 5). MAP kinase activity in the seven normal breast samples, one fibroadenoma, and three group A breast cancers was 0.09 ± 0.05, 0.18, and 0.20 ± 0.13 pmol/min/mg protein, respectively. Although the mean MAP kinase activity was approximately two-fold higher in the breast cancers than in the normal samples, the difference between the two groups was not statistically significant.

In six group B breast cancers, mean MAP kinase activity was 0.52 ± 0.22 pmol/min/mg protein, which


Figure 4. Immunohistochemical staining for EGF and ErbB-2 receptor expression. Paraffin-embedded tissue sections from the tumors of patient number 28 (panels A and B) and patient number 27 (panel C) were fixed and stained with an anti-ErbB-2 receptor antibody (panel A) or an anti-EGF receptor antibody (panels B and C) as described in Methods. The scale bar in all three panels is 50 μm. Note in panels A and B staining of the plasma membrane without cytoplasmic staining.

was significantly higher ($p < 0.01$) than in normal tissue. Therefore, samples with high Ras activation had high MAP kinase activity and the approximately four-fold higher Ras activation in the group B cancers compared to normal breast tissue was reflected in a greater than five-fold increase in MAP kinase activity.

Figure 5. MAP kinase activity in representative samples of patient cohort. MAP kinase was immunoprecipitated from frozen cells obtained as described in Figure 1 and MAP kinase activity was measured following phosphorylation of myelin basic protein. For each sample, the data are the mean ±SD of at least two independent measurements performed in duplicate. The designation of group A and B cancers is as in Figure 2.

Ras activation and map kinase activity in human breast cancer cell lines

We examined the effect of growth factors on Ras activation and MAP kinase activity in three well-characterized breast cancer cell lines: MCF-7 cells lacking known genetic mutations in Ras or growth factor receptors; MDA-MB-453 cells which overexpress the ErbB-2 receptor; and MDA-MB-231 cells which contain an activating K-*ras*, codon 12 mutation.

In serum-containing medium, Ras activation was 4.5% in MCF-7 cells (Figure 6A), comparable to Ras activation in normal breast tissue and the group A cancers; Ras activation decreased to 2% in serum-starved MCF-7 cells with EGF or serum increasing Ras activation by approximately four-fold. In MDA-MB-453 cells, Ras activation was high in serum-containing medium (16%, Figure 6B), comparable to the group B cancers, decreased to 8% under serum starvation and increased by ∼3.5- and ∼1.5-fold on adding EGF or serum, respectively. In addition to overexpressing the ErbB-2 receptor, MDA-MB-453 cells also express the ErbB-3 and ErbB-4 receptors [36, 37] and, receptor heterodimerization between the ErbB-2 receptor and the ErbB-3 or ErbB-4 receptor likely

explains the cells' responsiveness to EGF and serum [36–38]. In MDA-MB-231 cells, Ras activation was high, between 18 and 30%, changing little under all conditions (Figure 6C). These cells, therefore, exhibited similar Ras activation as in five of the 11 group B cancers. Thus, normal breast tissue and the group A cancers were similar to cells without any genetic mutations, and the group B cancers were similar to ErbB-2-overexpressing cells treated with growth factors and to cells with an activating K-*ras* mutation. An anti-ErbB-2 antibody decreased Ras activation by approximately 50% in serum-stimulated MCF-7 and MDA-MB-453 cells but was without effect when the cells were serum-starved (data not shown).

When we measured MAP kinase activity in the cell lines, we found that in serum-starved MCF-7 cells enzyme activity was 0.08 pmol/min/mg protein and increased ∼3.5-fold with EGF. The basal activity was similar to normal breast tissue and the EGF-stimulated activity was similar to activity in the fibroadenomas and group A cancers. MAP kinase activity in serum-starved MDA-MB-453 cells was 0.25 pmol/mg/min and increased ∼1.8-fold with EGF; the EGF-stimulated values are similar to activity in the group B cancers. MAP kinase activity in the MDA-MB-231 cells was high under basal conditions and was not influenced by growth factors. Thus, as for Ras activation, cells overexpressing the ErbB-2 receptor required growth factors for maximal MAP kinase stimulation whereas MAP kinase activity was independent of culture conditions in cells containing an activating *ras* mutation. Moreover, normal breast tissue and the group A cancers exhibited similar MAP kinase activity as MCF-7 cells and serum-starved MDA-MB-453 cells, and the group B cancers had similar MAP kinase activity as growth factor-treated MDA-MB-453 cells and the MDA-MB-231 cells.

Discussion

Using an enzyme-based method, we found Ras was highly activated in 11 of 20 breast cancers compared to normal breast tissue; MAP kinase activity was significantly elevated in these 11 cancers compared to normal tissue. During the course of these studies, Sivaraman et al. reported an approximate 4.5-fold increase in MAP kinase activity in 11 breast cancers compared to six benign breast lesions [16]. When the group A and group B cancers in our cohort are combined, we also find about a four-fold

Figure 6. Ras activation in human breast cancer cell lines. Ras activation was measured as described in Figure 2 in three human breast cancer cell lines: (A), MCF-7 cells with no known genetic mutations; (B), MDA-MB-453 cells which overexpress the ErbB-2 receptor; and (C), MDA-MB-453 cells with a mutation in K-*ras*, codon 12. Cells were grown in serum-containing medium (log phase), in serum-free medium for 72 h (serum starved), and in serum-free medium stimulated for 5 mim with either 20% fetal bovine serum (FBS) or 100 ng/ml EGF (EGF). The data are the mean ±S.D. of at least three independent experiments performed in duplicate. Note the difference in the ordinate scale between the MCF-7 cells and the MDA-MB-453 and MDA-MB-231 cells.

increase in MAP kinase activity relative to the normal samples. The Sivaraman group did not assess Ras activation or EGF or ErbB-2 receptor expression nor did they measure MAP kinase activation in cultured cell lines.

The mean Ras activation of 17% in the group B cancers is likely to be of physiological significance for the following reasons. First, as already mentioned, increased Ras activation in these cancers was associated with increased MAP kinase activity. Second, we and others have found in cells transfected with a mutated, constitutively-active Ras that Ras activation is in the range of 15–30% [24, 25]. This seemingly low degree of Ras activation is sufficient to transform cells by several criteria including tumorigenicity in nude mice [39, 40]. And third, we have found Ras

activation in the range of 20–30% in pancreatic and colonic adenocarcinomas which have activating K-*ras* mutations (unpublished observations); *ras* mutations in pancreatic and colonic carcinomas clearly play an etiologic role in the development of these cancers [41, 42]. The importance of Ras activation to breast cancer cell growth was recently underscored by Stevenson et al. who showed that a dominant negative Shc inhibited colony formation in several breast cancer cell lines and that an activated Ras restored the cells growth potential [43].

Nine of the 20 breast cancers expressed the EGF receptor which is similar to that reported in the literature [7–9] but we did not find an inverse correlation between EGF receptor expression and estrogen receptor status as reported in other studies [7, 8]. Ten

of the 20 breast cancers expressed the ErbB-2 receptor which is higher than generally reported but can be explained by the relatively small sample size [4, 5, 12]. We did not find expression of the c-FMS receptor or of the truncated constitutively-active EGF receptor, ΔEGFR, in our patient cohort; the c-FMS receptor is positive in only ~15% of breast cancers [14, 15] and the prevalence of the ΔEGFR in breast cancer is not yet well defined [13].

The data from the breast cancer cell lines related well to the data in the primary breast samples. Specifically, Ras activation in MCF-7 cells, which have no known genetic mutations in *ras* or in growth factor receptors, was in the range of that found in normal breast samples and the group A cancers, both in logarithmically growing cells and after EGF or serum stimulation. In MDA-MB-453 cells, which overexpress the ErbB-2 receptor, Ras activation was similar to the group B cancers, both during logarithmic growth and EGF or serum treatment. The MDA-MB-231 cells, which have an activating K-*ras* mutation, showed constitutively-elevated Ras activation unaffected by growth conditions with activation levels in the range of the group B cancers.

Seven of the 11 cancers with increased Ras activation co-expressed the EGF and ErbB-2 receptors and the other four cancers with high Ras activation expressed one of these two receptors. The ErbB-2 receptor has no known specific ligand and it must heterodimerize with the EGF, ErbB-3 or ErbB-4 receptor to be activated [44–46]. In the seven cancers co-expressing the EGF and ErbB-2 receptors, it is possible that the malignant tissue contained sufficient ligand to induce heterodimerization of these two receptors. Heterodimers of EGF and ErbB-2 can bind any of several growth factors including EGF, amphiregulin, betacellulin, transforming growth factor-alpha (TGF-α) or heparin-binding EGF-related growth factor, all of which may play a pathogenetic role in breast cancer [47–50]. In the two cancers with high Ras activation expressing only the ErbB-2 receptor, it may have dimerized with the ErbB-3 or ErbB-4 receptor; the ErbB-3 receptor shows increased expression in some breast cancers and the ErbB-4 receptor was found recently in nine of 12 breast cancers [51–53]. Since only two cancers with high Ras activation expressed the ErbB-2 receptor in the absence of the EGF receptor, it did not seem indicated to assess all 20 of the malignant samples for expression of both the ErbB-3 and ErbB-4 receptors. In the two cancers with high Ras activation expressing only the EGF

receptor, it is likely there was sufficiently high concentrations in the extracellular milieu of EGF, or some other EGF-like ligand, to induce receptor dimerization and, thereby, activate Ras. As is well known, overexpression of either the ErbB-2 or EGF receptor is associated with a poor clinical prognosis [4, 5, 7–9, 12] and our data suggest that the reason for a more malignant phenotype of these tumors may be because the cells are exposed to sufficient growth factors to activate Ras and MAP kinase.

Herceptin, an anti-ErbB-2 monoclonal antibody is the newest agent in the treatment of breast cancer and its use is based partially on the premise that downstream targets of ErbB-2, e.g., Ras and MAP kinase, are activated in breast cancer [54]. Our data with an anti-ErbB-2 antibody provide mechanistic support for Ras inhibition by herceptin. The finding that the antibody inhibited Ras activation only in the presence of growth factors may explain some of the variability in patient responses to herceptin. Several Ras inhibitors are in clinical trials and in animal models they are most effective in tumors exhibiting activated Ras, although their mechanism of action likely includes inhibition of other Ras-related proteins [19–22, 55, 56]. In addition, an oncolytic reovirus has been described which requires activated Ras for its tumorcidal properties [23]. By assessing Ras activation in tumors, it should be possible to determine *a priori*, prior to initiating treatment, whether a particular cancer is likely to respond to one of these new therapeutic approaches. Since we and others have found ErbB-2 receptor expression in non-malignant breast tissue [35], and in a cancer with low Ras activation, assessing receptor expression may not be sufficient. Similarly, assessing MAP kinase activity provides information only about a single mitogenic pathway, whereas it is clear that Ras transmits mitogenic signals through several different pathways [17, 18]. Moreover, the method for assessing Ras activation lends itself well to automation allowing rapid processing of multiple tumor samples. Thus, assessing Ras activation in breast cancer may have some advantages over assessing receptor expression or MAP kinase activity and may provide a basis for new treatment strategies of this disease.

Acknowledgements

References

1. Barbacid M: *Ras* genes. Annu Rev Biochem 56: 779–827, 1987
2. Bos JL: *Ras* oncogenes in human cancer: A review. Cancer Res 49: 4682–4689, 1989
3. Dickson RB, Gottardis MM, Merlino GT: Molecular insights into breast cancer from transgenic mouse models. BioEssays 13: 591–596, 1991
4. Slamon D, Clark G, Wong S, Levin W, Ulirich A, McGuire W: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/*neu* oncogene. Science 235: 177–182, 1987
5. Lacroix H, Iglehart JD, Skinner MA, Kraus MH: Overexpression of *erb*B-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145–151, 1989
6. Clark GJ, Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35: 133–144, 1995
7. Klijn J, Bems P, Schmitiz P, Foekens J: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocrine Rev 13: 3–17, 1992
8. Sainbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AJ: Epidermal-growth-factor receptor status as predictor of early recurrence of death from breast cancer. Lancet i 1398–1402, 1987
9. Newby JC, Hern RP, Leek RD, Smith IE, Harris AL, Dowseff M: Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clincal relevance in breast cancer. Br J Cancer 71: 1237–1242, 1995
10. Earp SH, Dawson TL, Li XO, Yu H: Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115–132, 1995
11. Slamon DJ, Godolphin W, Jones L, Holt J, Wong S, Keith D, Levin W, Stuart S, Udove J, Ullrich A, Press M: Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
12. Iglehart JD, Kraus MH, Langton BC, Huper G, Kems BJ, Marks JR: Increased *erb*B-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701–6707, 1990
13. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55: 5536–5539, 1995
14. Kacinski BM: CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 27: 79–85, 1995
15. Kacinski BM, Scata KA, Carter D, Yee LD, Sapi E, King BL, Chambers SK, Jones MA, Pirro MH, Stanley BR, Rohrschneider LR: *FMS* (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas *in vivo* and *in vitro*. Oncogene 6: 941–952, 1991
16. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478–1483, 1997
17. Marshall M: Ras target proteins in eukaryotic cells. FASEB J 9: 1311–1318, 1995
18. Lacal JC, Carnero A: Regulation of Ras proteins and their involvement in signal transduction pathways (Review). Oncol Rep 1: 677–693, 1994
19. Rowinsky EK, Windle JJ, von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17: 3631–3652, 1999
20. Kohl NE, Wilson FR, Mosser SD, Giuliani B, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A: Protein famesyltransferase inhibitors block the growth of *ras*-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141–9145, 1994
21. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55: 5310–5314, 1995
22. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, DeSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Kral AM, Miller PJ, Mosser SD, O'Neill TJ, Rands B, Schaber MD, Gibbs JB, Oliff A: Inhibition of famesyltransferase induces regression of mammary and salivary carcinomas in Ras transgenic mice. Nature Medicine 1: 792–797, 1995
23. Coffey MC, Strong JE, Forsyth PA, Lee PWK: Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332–1334, 1998
24. Scheele JS, Rhee JM, Boss GR: Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: Comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc Natl Acad Sci USA 92: 1097–1100, 1995
25. Guha A, Lau N, Huvar I, Gutmann D, Provias J, Pawson T, Boss G: Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 12: 507–513, 1996
26. Guha A, Feldkamp M, Lau N, Huvar I, Boss G, Pawson T: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15: 2755–2765, 1997
27. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Su Huang H-J: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated EGF receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271: 25639–25645, 1996
28. Hattori S, Clanton DJ, Satoh T, Nakamura S, Kaziro Y, Kawakita M, Shih TY: Neutralizing monoclonal antibody against *ras* oncogene product p21 which impairs guanine nucleotide exchange. Mol Cell Biol 7: 1999–2002, 1987
29. Suhasini M, Li H, Lohmann SM, Boss GR, Pilz RB: Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway. Mol Cell Biol 18: 6983–6994, 1998
30. Jiang W, Kahn SM, Ouillem JG, Lu S-H, Weinstein TB: Rapid detection of *ras* oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. Oncogene 4: 923–928, 1989
31. Brunk C, Jones K, James T: Assay for nanogram quantities of DNA in cellular homogenates. Anal Biochem 92: 497–500, 1979
32. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248–254, 1976
33. Koffa M, Malamou-Mitsi V, Agnantis NJ, Spandidos DA: Mutational activation of K-ras oncogene in human breast tumors. Int J Oncology 4: 573–576, 1994

34. Capella G, Cronauer-Mitra S, Peinado MA, Perucho M: Frequency and spectrum of mutations at codons i2 and 13 of the K-*ras* gene in human tumors. Env Health Persp 93: 125–131, 1991

35. Rohan TE, Hartwick W, Miller AB, Kandel RA: Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 90: 1262–1269, 1998

36. Chan S, Antoniucci D, Fok K, Alajoki M, Harkins R, Thompson S, Wada G: Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3. J Biol Chem 270: 22608–22613, 1995

37. Mixan B, Cohen BD, Bacus SS, Fell HP, Siegall CB: Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity. Oncogene 16: 1209–1215, 1998

38. Alimandi M, Wang L-M, Bottaro D, Lee C-C, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH: Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. EMBO J 16: 5608–5617, 1997

39. Pozzatti R, Muschel R, Williams J, Padmanabhan R, Howard B, Liotta LA, Khoury G: Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials. Science 232: 223–227, 1986

40. Der CJ, Finkel T, Cooper GM: Biological and biochemical properties of human *ras* H genes mutated at codon 61. Cell 44: 167–176, 1986

41. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85–88, 1993

42. Pellegata NS, Sessa F, Renault Beal: K-*ras* and *p53* gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54: 1556–1562, 1994

43. Stevenson LE, Ravichandran KS, Frackelton AR, Jr.: Shc dominant negative disrupts cell cycle progression in both G_0-G_1 and G_2-M of ErbB2-positive breast cancer cells. Cell Growth Dif 10: 61–71, 1999

44. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254–264, 1996

45. Carraway K, Cantley L: A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 78: 5–8, 1994

46. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96: 4995–5000, 1999

47. Buday L, Downward J: Epidermal growth factor regulates the exchange rate of guanine nucleotides on $p21^{ras}$ in fibroblasts. Mol Cell Biol 13: 1903–1910, 1993

48. Sasaoka T, Langlois W, Leitner J, Draznin B, Olefsky J: The signaling pathway coupling epidermal growth factor receptors to activation of $p21^{ras}$. J Biol Chem 269: 32621–3265, 1994

49. Riese DJ, Kim ED, Elenius K, Buckley S, Klagsbrun M, Plowman GD, Stem DF: The epidermal growth factor receptor couples transforming growth factor-α, heparin-binding epidermal growth factor-like factor, and amphiregulin to neu, erbB-3, and erbB-4. J Biol Chem 271: 20047–20052, 1996

50. Beerli RR, Hynes NE: Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differ in their biological activities. J Biol Chem 271: 6071–6076, 1996

51. Kraus M, Issing W, Miki T, Popescu N, Aaronson S: Isolation and characterization of *ERBB3*, a third member of the *ERBB*/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193–9197, 1989

52. Kraus M, Fedi P, Starks V, Muraro R, Aaronson S: Demonstration of ligand-dependent signaling by the *erbB-3* tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90: 2900–2904, 1993

53. Sawyer L, Hues I, Page M, Crompton M, Dean C: Two erbB-4 transcripts are expressed in normal breast and in most breast cancers. Oncogene 17: 919–924, 1998

54. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson ICa, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996

55. Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransrase inhibitors suppress ras transformation by interfering with Rho activity. Mol Cell Biol 1513: 6613–6622, 1995

56. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating flinction of RhoB. J Biol Chem 272: 15591–15594, 1997

Address for offprints and correspondence: Gerry R. Boss, Department of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0652, *Tel.:* 858-534-8805; *Fax:* 858-534-1421; e-mail: gboss@ucsd.edu